Treatment is prolonged and requires meticulous monitoring, but M. kansasii isÂ a treatable infection. With rifampin-based regimens, the relapse rate is very low, and the prognosis is good. A study of 302 patients followed over more than a 50-year period (1952-1995), showed a mortality rate of 11%, but this included both immunocompromised and non-immunocompromised patients.